385 related articles for article (PubMed ID: 9834008)
1. Resistance to activated protein C in women using oral contraceptives.
Spannagl M; Dick A; Assmann A; Heinemann L; Schramm W
Semin Thromb Hemost; 1998; 24(5):423-30. PubMed ID: 9834008
[TBL] [Abstract][Full Text] [Related]
2. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives.
Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Koster T; Bertina RM; Vandenbroucke JP
Thromb Haemost; 1998 Sep; 80(3):382-7. PubMed ID: 9759614
[TBL] [Abstract][Full Text] [Related]
3. Thrombotic risk factors and oral contraception.
Bokarewa MI; Falk G; Sten-Linder M; Egberg N; Blombäck M; Bremme K
J Lab Clin Med; 1995 Sep; 126(3):294-8. PubMed ID: 7665978
[TBL] [Abstract][Full Text] [Related]
4. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
[TBL] [Abstract][Full Text] [Related]
5. Thrombophilic mechanisms of OCs.
Comp PC
Int J Fertil Womens Med; 1997; Suppl 1():170-6. PubMed ID: 9168376
[TBL] [Abstract][Full Text] [Related]
6. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
Graf LL; Welsh CH; Qamar Z; Marlar RA
Am J Clin Pathol; 2003 Jan; 119(1):52-60. PubMed ID: 12520697
[TBL] [Abstract][Full Text] [Related]
7. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
[TBL] [Abstract][Full Text] [Related]
8. Effects of oral contraceptives on hemostasis and thrombosis.
Rosing J; Tans G
Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S375-82. PubMed ID: 10368524
[TBL] [Abstract][Full Text] [Related]
9. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
Curvers J; Thomassen MC; Rimmer J; Hamulyak K; van der Meer J; Tans G; Preston FE; Rosing J
Thromb Haemost; 2002 Jul; 88(1):5-11. PubMed ID: 12152677
[TBL] [Abstract][Full Text] [Related]
10. Activated protein C resistance--a major risk factor for thrombosis.
Rosén SB; Sturk A
Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
[TBL] [Abstract][Full Text] [Related]
11. Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels.
Legnani C; Cini M; Cosmi B; Poggi M; Boggian O; Palareti G
Haematologica; 2004 Nov; 89(11):1347-51. PubMed ID: 15531457
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
Petersen KR
Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
[TBL] [Abstract][Full Text] [Related]
13. [The Bavarian Thromboembolic Risk Cohort Study (BATER). Study protocol, state of the investigation and first results].
Schramm W; Heinemann LA; Spannagl M; Dick A; Assmann A
Dtsch Med Wochenschr; 2000 Jan; 125(1-2):2-6. PubMed ID: 10650817
[TBL] [Abstract][Full Text] [Related]
14. Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation.
De Mitrio V; Marino R; Scaraggi FA; Di Bari L; Giannoccaro F; Petronelli M; Ranieri P; Tannoia N; Schiraldi O
Blood Coagul Fibrinolysis; 1999 Oct; 10(7):409-16. PubMed ID: 10695766
[TBL] [Abstract][Full Text] [Related]
15. Acquired APC resistance and oral contraceptives: differences between two functional tests.
Curvers J; Thomassen MC; Nicolaes GA; Van Oerle R; Hamulyak K; Hemker HC; Tans G; Rosing J
Br J Haematol; 1999 Apr; 105(1):88-94. PubMed ID: 10233368
[TBL] [Abstract][Full Text] [Related]
16. Oral contraceptive use in women with poor anticoagulant response to activated protein C but not carrying the factor V Leiden mutation increases the risk of venous thrombosis.
Legnani C; Cini M; Cosmi B; Mattarozzi S; Lo Manto G; Palareti G
Thromb Haemost; 2004 Apr; 91(4):712-8. PubMed ID: 15045132
[TBL] [Abstract][Full Text] [Related]
17. Molecular biology and pathophysiology of APC resistance: current insights and clinical implications.
Rosing J; Hemker HC; Tans G
Semin Thromb Hemost; 1998; 24(4):329-35. PubMed ID: 9763350
[TBL] [Abstract][Full Text] [Related]
18. Resistance to activated protein C in healthy women taking oral contraceptives.
Olivieri O; Friso S; Manzato F; Guella A; Bernardi F; Lunghi B; Girelli D; Azzini M; Brocco G; Russo C
Br J Haematol; 1995 Oct; 91(2):465-70. PubMed ID: 8547095
[TBL] [Abstract][Full Text] [Related]
19. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.
Tans G; Curvers J; Middeldorp S; Thomassen MC; Meijers JC; Prins MH; Bouma BN; Büller HR; Rosing J
Thromb Haemost; 2000 Jul; 84(1):15-21. PubMed ID: 10928463
[TBL] [Abstract][Full Text] [Related]
20. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives.
Aznar J; Vayá A; Estellés A; Mira Y; Seguí R; Villa P; Ferrando F; Falcó C; Corella D; España F
Haematologica; 2000 Dec; 85(12):1271-6. PubMed ID: 11114134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
